🇺🇸 Palbociclib in combination with AI in United States

Palbociclib in combination with AI (palbociclib-in-combination-with-ai) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Palbociclib in combination with AI in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Palbociclib in combination with AI approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Palbociclib in combination with AI in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Palbociclib in combination with AI cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.